The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Prognostic value of circulating tumor DNA for progression-free survival in patients with locally advanced dMMR/MSI-H colorectal cancer managed without surgery.
 
Michael LaPelusa
No Relationships to Disclose
 
Wei Qiao
No Relationships to Disclose
 
Bryan Iorgulescu
No Relationships to Disclose
 
Francis A San Lucas
No Relationships to Disclose
 
Keyur Patel
Consulting or Advisory Role - Astellas Pharma; Astellas Pharma; Syros Pharmaceuticals
 
Deepak Bhamidipati
No Relationships to Disclose
 
Jane Thomas
No Relationships to Disclose
 
Y. Nancy You
No Relationships to Disclose
 
Wai Foo
No Relationships to Disclose
 
Dipen Maru
No Relationships to Disclose
 
Selvi Thirumurthi
No Relationships to Disclose
 
Van Morris
Consulting or Advisory Role - Bristol Myers Squibb Foundation; Incyte; Novartis; Regeneron; Scandion Oncology
Research Funding - Apollo Therapeutics (Inst); Bicara Therapeutics (Inst); BioNTech (Inst); Bristol-Myers Squibb (Inst); Pfizer (Inst); Redx Pharma (Inst); Sumitomo Pharma Oncology (Inst)
 
Scott Kopetz
Stock and Other Ownership Interests - Frontier Medicines; Lutris; Navire
Consulting or Advisory Role - Agenus; Amgen; AmMax Bio; Arcus Biosciences; AstraZeneca; AVEO; Bayer Health; BeiGene; Boehringer Ingelheim; Bridgebio; Bristol-Myers Squibb/Medarex; Carina Biotech; Clasp Therapeutics; Cytovation; Dewpoint Therapeutics; EMD Serono; Flame Biosciences; Frontier Medicines; Genentech; Harbinger Oncology, Inc; Ikena Oncology; Kestrel Therapeutics; Marengo Therapeutics; Merck; Mirati Therapeutics; Pfizer; Replimune; Revolution Medicines; Roche; SageMedic; SERVIER; Sibylla; T-Cypher Bio; Tachyon Therapeutics; XAIRA Therapeutics; Zentalis; Zentalis
Research Funding - Amgen; Boehringer Ingelheim; BridgeBio; Daiichi Sankyo; EMD Serono; Genentech/Roche; Guardant Health; Lilly; Pfizer; Zentalis
 
Michael Overman
Consulting or Advisory Role - 3D Medicines; Array BioPharma; Bristol-Myers Squibb; Eisai; Gritstone Bio; Janssen; Janssen; MedImmune; Merck; Novartis; Pfizer; Roche/Genentech; Simcere
Research Funding - Bristol-Myers Squibb; MedImmune; Merck; Roche
 
Kaysia Ludford
Research Funding - Merck (Inst)